Granted Patent
B2
US 12,447,162 · App. 18/759,278 · Granted Oct 21, 2025
Compositions and methods for the treatment of meibomian gland dysfunction
Inventors:
Yair Alster (Tel Aviv, IL); Omer Rafaeli (Udim, IL); Kirsten Angela MacFarlane (Menlo Park, CA); Cary Reich (Santa Barbara, CA); Shimon Amselem (Rehovot, IL); Doron Friedman (Karmei Yosef, IL)
Assignee:
Azura Ophthalmics Ltd.
A61K31/60A61K8/22A61K8/23A61K9/0048A61K9/06A61K31/122A61K31/17A61K31/19A61K31/327A61K31/4015A61K31/555A61K33/04A61K35/04A61K9/0014
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
Claims (27)
1. A method for improving meibomian gland function in an individual in need thereof, the method comprising administering to an eyelid of the individual a composition comprising about 0.1% to 1.0% selenium disulfide by weight and an oleaginous base.
2. The method of claim 1 , wherein the composition comprises about 0.5% selenium disulfide by weight.
3. The method of claim 2 , wherein the method improves secretion from meibomian gland of the individual.
4. The method of claim 2 , wherein the method increases secretion from meibomian gland of the individual.
5. The method of claim 2 , wherein the method improves the quality of meibum of the individual.
6. The method of claim 2 , wherein the method increases the number of open meibomian glands in the individual.
7. The method of claim 2 , wherein the administration increases the number of open meibomian glands, increases secretion from meibomian gland, and/or improves the quality of meibum of the individual.
8. The method of claim 7 , wherein the composition is an ointment.
9. The method of claim 8 , wherein the composition is an ophthalmically-acceptable pharmaceutical composition.
10. The method of claim 9 , wherein the administration is topical.
11. The method of claim 1 , wherein the composition comprises about 0.5% or about 1.0% selenium disulfide by weight.
12. The method of claim 11 , wherein the composition is administered to the individual twice a week.
13. The method of claim 12 , wherein the composition is administered to a lower eyelid margin of the individual.
14. A method for opening a meibomian gland in an individual in need thereof, the method comprising administering to an eyelid of the individual a composition comprising about 0.1% to 1.0% selenium disulfide by weight and an oleaginous base.
15. The method of claim 14 , wherein the composition comprises about 0.5% selenium disulfide by weight.
16. The method of claim 15 , wherein the method improves secretion from meibomian gland of the individual.
17. The method of claim 15 , wherein the method increases secretion from meibomian gland of the individual.
18. The method of claim 15 , wherein the method improves the quality of meibum of the individual.
19. The method of claim 15 , wherein the method improves meibomian gland function of the individual.
20. The method of claim 15 , wherein the method increases the number of open meibomian glands in the individual.
21. The method of claim 14 , wherein the administration increases the number of open meibomian glands, increases secretion from meibomian gland, and/or improves the quality of meibum of the individual.
22. The method of claim 21 , wherein the composition is an ointment.
23. The method of claim 22 , wherein the composition is an ophthalmically-acceptable pharmaceutical composition.
24. The method of claim 23 , wherein the administration is topical.
25. The method of claim 24 , wherein the composition comprises about 0.5% or about 1.0% selenium disulfide by weight.
26. The method of claim 25 , wherein the composition is administered to the individual twice a week.
27. The method of claim 26 , wherein the composition is administered to a lower eyelid margin of the individual.
Assignments (1)
CHANGE OF NAME
Recorded Jul 24, 2025
From: M.G. THERAPEUTICS LTD.
To: AZURA OPHTHALMICS LTD.
Reel/Frame 072210/0050 →
Continuity (9)
Provisional Application
62065716
· Oct 19, 2014
References Cited (203)
US 3236730A
· Galin
· 1966
[cited by applicant]
US 5645827A
· Marlin et al.
· 1997
[cited by applicant]
US 5798121A
· Cauwet et al.
· 1998
[cited by applicant]
US 6153607A
· Pflugfelder et al.
· 2000
[cited by applicant]
US 6348508B1
· Denick, Jr. et al.
· 2002
[cited by applicant]
US 7288259B2
· Sanders et al.
· 2007
[cited by applicant]
US 8420699B1
· Dubow
· 2013
[cited by applicant]
US 8449928B2
· Gilbard et al.
· 2013
[cited by applicant]
US 8455016B2
· Maskin
· 2013
[cited by applicant]
US 9463201B2
· Alster et al.
· 2016
[cited by applicant]
US 20030228299A1
· Droy-Lefaix et al.
· 2003
[cited by applicant]
US 20040171561A1
· Popp
· 2004
[cited by applicant]
US 20050124690A1
· Yoon et al.
· 2005
[cited by applicant]
US 20050197614A1
· Pritchard et al.
· 2005
[cited by applicant]
US 20060188471A1
· Podolsky et al.
· 2006
[cited by applicant]
US 20070082017A1
· Tseng et al.
· 2007
[cited by applicant]
US 20070166402A1
· Friedlaender et al.
· 2007
[cited by applicant]
US 20070269537A1
· Gupta
· 2007
[cited by applicant]
US 20070280924A1
· Daniels et al.
· 2007
[cited by applicant]
US 20080020044A1
· Alam et al.
· 2008
[cited by applicant]
US 20080242729A1
· Bollag
· 2008
[cited by applicant]
US 20090123527A1
· Alam et al.
· 2009
[cited by applicant]
US 20090214676A1
· Gao et al.
· 2009
[cited by applicant]
US 20090238810A1
· Nyunt
· 2009
[cited by applicant]
US 20100204317A1
· Hunt et al.
· 2010
[cited by applicant]
US 20110059925A1
· Donnenfeld
· 2011
[cited by applicant]
US 20110294897A1
· Aberg et al.
· 2011
[cited by applicant]
US 20120028929A1
· Power et al.
· 2012
[cited by applicant]
US 20120093876A1
· Ousler, III et al.
· 2012
[cited by applicant]
US 20120128763A1
· Maskin
· 2012
[cited by applicant]
US 20120264681A1
· Braiman-Wiksman et al.
· 2012
[cited by applicant]
US 20130184242A1
· Eini et al.
· 2013
[cited by applicant]
US 20130274214A1
· Brubaker
· 2013
[cited by applicant]
US 20130281390A1
· Brubaker
· 2013
[cited by applicant]
US 20130331768A1
· Nichamin
· 2013
[cited by applicant]
US 20130345185A1
· Mitra et al.
· 2013
[cited by applicant]
US 20140005171A1
· Aukunuru et al.
· 2014
[cited by applicant]
US 20140058340A1
· Guillon et al.
· 2014
[cited by applicant]
US 20140142055A1
· Hosseini et al.
· 2014
[cited by applicant]
US 20140142668A1
· Guillon et al.
· 2014
[cited by applicant]
US 20140206708A1
· Ren et al.
· 2014
[cited by applicant]
US 20180043024A1
· Sakurai et al.
· 2018
[cited by applicant]
US 20200179440A1
· Amselem et al.
· 2020
[cited by applicant]
US 20220226367A1
· Amselem et al.
· 2022
[cited by applicant]
CN 1093897A
· 1994
[cited by applicant]
CN 101612161A
· 2009
[cited by applicant]
CN 102038953A
· 2011
[cited by applicant]
CN 103002737A
· 2013
[cited by applicant]
CN 103037802A
· 2013
[cited by applicant]
CN 105456287A
· 2016
[cited by applicant]
EP 0930072A1
· 1999
[cited by applicant]
EP 1621191A1
· 2006
[cited by applicant]
EP 1915998A1
· 2008
[cited by applicant]
EP 2633852A1
· 2013
[cited by applicant]
EP 2664330A1
· 2013
[cited by applicant]
EP 2667877A2
· 2013
[cited by applicant]
EP 3206497A1
· 2017
[cited by applicant]
JP H07233057A
· 1995
[cited by applicant]
JP H11292793A
· 1999
[cited by applicant]
JP 2010510961A
· 2010
[cited by applicant]
JP 2010520210A
· 2010
[cited by applicant]
JP 2014518275A
· 2014
[cited by applicant]
JP 2015514722A
· 2015
[cited by applicant]
WO WO9611686A1
· 1996
[cited by applicant]
WO WO9724116A2
· 1997
[cited by applicant]
WO WO03035076A1
· 2003
[cited by applicant]
WO WO03050190A2
· 2003
[cited by applicant]
WO WO2005067892A1
· 2005
[cited by applicant]
WO WO2006137426A1
· 2006
[cited by applicant]
WO WO2007070463A2
· 2007
[cited by applicant]
WO WO2007133703A2
· 2007
[cited by applicant]
WO WO2008027069A1
· 2008
[cited by applicant]
WO WO2008068866A1
· 2008
[cited by applicant]
WO WO2008106228A2
· 2008
[cited by applicant]
WO WO2010006117A2
· 2010
[cited by applicant]
WO WO2011006079A2
· 2011
[cited by applicant]
WO WO2012092320A2
· 2012
[cited by applicant]
WO WO2012155062A1
· 2012
[cited by applicant]
WO WO2012161112A1
· 2012
[cited by applicant]
WO WO2013003731A2
· 2013
[cited by applicant]
WO WO2014078956A1
· 2014
[cited by applicant]
WO WO2015017316A2
· 2015
[cited by applicant]
WO WO2015022546A1
· 2015
[cited by applicant]
WO WO2015169728A1
· 2015
[cited by applicant]
WO WO2016063130A1
· 2016
[cited by applicant]
WO WO2017055924A2
· 2017
[cited by applicant]
WO WO2017178892A2
· 2017
[cited by applicant]
WO WO2017182885A2
· 2017
[cited by applicant]
WO WO2020208418A1
· 2020
[cited by applicant]
Jagavkar (Appraisal of Efficacy of Two Anti Dandruff Formulation, Indian J Dermatol Venerbol Lepr, vol. 45, Iss 5, 1979). (Year: 1979).
[cited by examiner]
Akyol-Salman et al. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther 26(4):329-333 (2010).
[cited by applicant]
Anonymous. Ointments and Types of ointment bases. Pharmaceutical Drugs and Dosage: Semisolid dosage forms. Available at https://www.pharmacy180.com/article/ointments-and-types-of-ointment-bases-2856/ (2019).
[cited by applicant]
BAHN. The treatment of seborrheic blepharitis. South Med 47(8):749-53 (1954).
[cited by applicant]
Barrault et al. Immortalized sebocytes can spontaneously differentiate into a sebaceous-like phenotype when cultured as a 3D epithelium. Exp Dermatol 21:299-319 (2012).
[cited by applicant]
Butovich et al. Human tear film and meibum. Very long chain wax esters and (O-acyl)-omega-hydroxy fatty acids of meibum. J Lipid Res 50(12):2471-2485 (2009).
[cited by applicant]
Chalmers et al. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performance. Optom Vis Sci. 89:1435-1442 (2012).
[cited by applicant]
Chalmers et al. Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8): Use of an 8-Item Habitual Symptom Score to Reflect Change in Overall Opinion on Contact Lens Performance. Invest Ophthalmol Vis Sci 50:6337 (2009).
[cited by applicant]
Chalmers et al. Cutoff score and responsiveness of the 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8) in a Large daily disposable contact lens registry. Cont. Lens. Anterior Eye. 39(5):342-52 (2016).
[cited by applicant]
Charlton et al. Topical urea as a treatment for non-infectious keratopathy. Acta Ophthalmol Scand 74(4):391-394 (1996).
[cited by applicant]
Chew et al. An instrument for quantifying meibomian lipid on the lid margin: the Meibometer. Curr Eye Res 12(3):247-254 (1993).
[cited by applicant]
Cohen et al., Use of Selsun In Blepharitis Marginalis. American Journal of Ophthalmology 38(4):560-562 (1954).
[cited by applicant]
Co-pending U.S. Appl. No. 18/665,222, inventors Friedman; Doron et al., filed May 15, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/759,260, inventors Alster; Yair et al., filed Jun. 28, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/789,422, inventors Bosworth; Charles et al., filed Jul. 30, 2024.
[cited by applicant]
De Villiers. Chapter 23: Ointment Base. A Practical Guide to Contemporary Pharmacy Practice. Publisher: Wolters Kluwer Health/Lippincott Williams & Wilkins. Editors: Judith E. Thompson (pp. 277-290) (2009).
[cited by applicant]
Driver et al. Meibomian Gland Dysfunction. Survey of Ophthalmology 40(5):343-367 (1996).
[cited by applicant]
Efron et al. Lid Wiper Epitheliopathy. Prog Retin Eye Res. 53:140-174 (2016).
[cited by applicant]
Foulks et al. The TFOS International Workshop on Contact Lens Discomfort: Report of the Subcommittee on Clinical Trial Design and Outcomes. Invest Ophthalmol Vis Sci 54:TFOS157-TFOS182 (2013).
[cited by applicant]
Geerling et al., The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. The Association for Research in Vision and Ophthalmology…
[cited by applicant]
Heiligenhaus et al. Therapy of dry eye disorders [Therapie von Benetzungsstorungen]. Klin Monatsbl Augenheilkd 204:162-168 (1994) (English Summary).
[cited by applicant]
Itoh et al. The Molecular Mechanism of the Synthesis of the 21st Amino Acid, Selenocysteine. Journal of Japanese Crystal Society 56(3):186-193 (2014) (English Abstract).
[cited by applicant]
Knop et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. IOVS 52(4):1938-1978 (2011).
[cited by applicant]
Koenig et al. Organic Sulfur Derivatives. V.2 Preparation and Properties of Some Long-Chain Mercapto Acids and Related Compounds. J Org Chem 23:1525-1530 (1958).
[cited by applicant]
Korb et al. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc 51(3):243-251 (1980).
[cited by applicant]
Lavyel, Selsunef Ointment To Treat Squamous Blepharitis. American Journal of Ophthalmology 49:820-821 (1960).
[cited by applicant]
Lindsley et al. Interventions for chronic blepharitis. Cochran Database Syst Rev 2012(5):CD005556 (2012).
[cited by applicant]
Maskin. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea 29(10):1145-1152 (2010).
[cited by applicant]
Millar et al. The effect of dietary and pharmacological manipulation of lipid production in the Meibomian and Harderian glands of the rabbit. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. Advances in Experimental …
[cited by applicant]
Nagymihalyi et al. The influence of eyelid temperature on the delivery of Meibomian oil. Exp Eye Res 78:367-370 (2004).
[cited by applicant]
Nederfors et al. Effects of the antihypertensive drug captopril on human salivary secretion rate and composition. Eur J Oral Sci 103(6):351-354 ( Dec. 1995) (Abstract).
[cited by applicant]
Nelson et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Definition and Classification Subcommittee. Invest Ophthalmol Vis Sci. 52(4):1930-1937 (2011).
[cited by applicant]
Nichols et al. Dual-Polymer Drops, Contact Lens Comfort, and Lid Wiper Epitheliopathy. Optom Vis Sci. 93(8):979-86 (2016).
[cited by applicant]
Nichols et al. The Performance of the Contact Lens Dry Eye Questionnaire as a Screening Survey for Contact Lens-related Dry Eye. Cornea 21(5):469-475 (2002).
[cited by applicant]
Nichols. The International Workshop on Meibomian Gland Dysfunction: Introduction. Invest Ophthalmol Vis Sci 52(4):1917-1921 (2011).
[cited by applicant]
Omali et al. Quantification of individual proteins in silicone hydrogel contact lens deposits. Mol Vis. 19:390-399 (2013).
[cited by applicant]
PCT/IB2015/02164 International Search Report and Written Opinion dated Mar. 29, 2016.
[cited by applicant]
PCT/IB2017/00542 International Search Report and Written Opinion dated Sep. 21, 2017.
[cited by applicant]
PCT/IB2020/000262 International Search Report and Written Opinion dated Aug. 12, 2020.
[cited by applicant]
PCT/US2016/01510 International Search Report and Written Opinion dated May 24, 2017.
[cited by applicant]
Post et al. Demodex Folliculorum and Blepharitis Arch. Dermatol. 88(3):298-302 (1963).
[cited by applicant]
Qiao et al. Emerging treatment options for meibomian gland dysfunction. Clinical Ophthalmology 7:1797-1803 (2013).
[cited by applicant]
Seifert et al. Immunocytochemical and ultrastructure evaluation of the distribution of nervous tissue and neuropeptides in meibomian gland. Graefe's Arch Clin Exp Ophthalmol 234:648-656 (1996).
[cited by applicant]
Sha. Ophthalmology. People's Military Medical Press. p. 138 (Apr. 30, 2013).
[cited by applicant]
Siddireddy et al. Predictive Potential of Eyelids and Tear Film in Determining Symptoms in Contact Lens Wearers. Optom Vis Sci 95(11):1035-1045 (2018).
[cited by applicant]
Thygeson et al. Seborrheic blepharitis. Trans Am Ophthalmol Soc. 52:173-88 (1954-1955).
[cited by applicant]
U.S. Appl. No. 14/732,622 Office Action dated Nov. 19, 2015.
[cited by applicant]
U.S. Appl. No. 15/269,833 Office Action dated Aug. 7, 2017.
[cited by applicant]
U.S. Appl. No. 15/269,833 Office Action dated Jan. 11, 2017.
[cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Apr. 25, 2019.
[cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Aug. 31, 2017.
[cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Mar. 14, 2018.
[cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Mar. 29, 2017.
[cited by applicant]
U.S. Appl. No. 15/279,301 Office Action dated Nov. 27, 2018.
[cited by applicant]
U.S. Appl. No. 16/019,253 Office Action dated May 16, 2019.
[cited by applicant]
U.S. Appl. No. 16/093,615 Office Action dated Dec. 22, 2020.
[cited by applicant]
U.S. Appl. No. 16/093,615 Office Action dated Jul. 6, 2020.
[cited by applicant]
U.S. Appl. No. 16/562,374 Office Action dated Oct. 30, 2019.
[cited by applicant]
U.S. Appl. No. 16/919,749 Office Action dated Oct. 5, 2020.
[cited by applicant]
U.S. Appl. No. 17/236,258 Office Action dated Oct. 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/320,731 Office Action dated Mar. 20, 2023.
[cited by applicant]
U.S. Appl. No. 17/357,749 Office Action dated Nov. 1, 2021.
[cited by applicant]
U.S. Appl. No. 17/536,986 Office Action dated Mar. 1, 2024.
[cited by applicant]
U.S. Appl. No. 17/723,090 Office Action dated May 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/119,251 Office Action dated Jul. 6, 2023.
[cited by applicant]
U.S. Appl. No. 18/665,222 Office Action dated Jul. 29, 2024.
[cited by applicant]
U.S. Appl. No. 16/795,497 Office Action dated Jul. 29, 2021.
[cited by applicant]
Willis et al. Meibomian gland function, lid wiper epitheliopathy, and dry eye symptoms. Investigative Ophthalmology & Visual Science 52(14):3740-3740 (2011).
[cited by applicant]
Wong et al. Selenium (Selsun) in the Treatment of Marginal Blepharitis. AMA Arch Ophthalmol 55(2):246-253 (1956).
[cited by applicant]
Young et al. Soft contact lens-related dryness with and without clinical signs. Optom. Vis. Sci. 89:1125-32 (2012).
[cited by applicant]
Zhang. Modern Dermatologic Therapeutics. People's Military Medical Press p. 187 (May 31, 2022).
[cited by applicant]